Scholar Rock Holding (SRRK) Accumulated Expenses (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Accumulated Expenses of $44.3 million in Q1 2026, up 120.49% quarter-over-quarter from $20.1 million in Q4 2025, and up 428.85% on a YoY basis from $8.4 million in Q1 2025.
Scholar Rock Holding (SRRK) Accumulated Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $44.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 428.85% year-over-year to $44.3 million; the TTM figure through Mar 2026 stood at $44.3 million (up 428.85% YoY), while the FY2025 annual figure was $20.1 million, down 35.26% from the prior year.
- Accumulated Expenses was $44.3 million for Q1 2026 at Scholar Rock Holding, up from $20.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $44.3 million in Q1 2026 to a low of $4.0 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $18.8 million across 5 years, with a median of $17.9 million in 2022.
- The sharpest annual moves came in 2022 and 2026: Accumulated Expenses sank 63.25% in 2022, then jumped 428.85% in 2026.
- A 5-year view of Accumulated Expenses shows it stood at $6.8 million in 2022, then surged by 200.72% to $20.4 million in 2023, then surged by 51.92% to $31.1 million in 2024, then plunged by 35.26% to $20.1 million in 2025, then surged by 120.49% to $44.3 million in 2026.
- The last three Accumulated Expenses figures came in at $44.3 million (Q1 2026), $20.1 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.35 Mn |
| Dec 31, 2025 | 20.11 Mn |
| Sep 30, 2025 | 22.74 Mn |
| Jun 30, 2025 | 44.12 Mn |
| Mar 31, 2025 | 8.39 Mn |
| Dec 31, 2024 | 31.07 Mn |
| Sep 30, 2024 | 29.26 Mn |
| Jun 30, 2024 | 21.89 Mn |
| Mar 31, 2024 | 6.11 Mn |
| Dec 31, 2023 | 20.45 Mn |
| Sep 30, 2023 | 17.40 Mn |
| Jun 30, 2023 | 13.81 Mn |
| Mar 31, 2023 | 4.05 Mn |
| Dec 31, 2022 | 6.80 Mn |
| Sep 30, 2022 | 6.58 Mn |
| Jun 30, 2022 | 17.89 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 17.46 Mn |
| Sep 30, 2021 | 17.90 Mn |
| Jun 30, 2021 | 15.45 Mn |